Humanin Research Guide: Mitochondrial-Derived Peptide, Neuroprotection, and Longevity Research

By Sam Smith

Humanin was found by accident. Researchers mapping gene expression in neurons that survived in Alzheimer’s disease tissue — the cells somehow still functional amid widespread degeneration — traced sequences to the mitochondrial 16S rRNA gene. The peptide encoded there, which Hashimoto et al. identified in 2001, blocked BAX-mediated apoptosis and protected neurons from amyloid-beta toxicity in culture. That was two decades ago. Since then, circulating Humanin levels appear to decline with age, to correlate inversely with all-cause mortality in centenarian studies (Muzumdar et al., 2010, Cell Metabolism), and to track with preserved cognitive function in epidemiological data. It’s one of a small group of mitochondrial-derived peptides for which there’s both mechanistic data and population-level correlation with longevity outcomes.

What is humanin and how was it discovered?

Humanin was found by looking in an unexpected place. Researchers mapping gene expression in the neuronal survivors of Alzheimer’s disease tissue — cells somehow still functional while surrounding neurons were dying — found sequences transcribed from a part of the genome that wasn’t supposed to produce protein: the mitochondrial 16S ribosomal RNA gene. Hashimoto et al. (2001, PNAS) described the peptide encoded there and showed it blocked BAX-mediated apoptosis in neurons challenged with amyloid-beta. That discovery established humanin as the first mitochondrial-derived peptide (MDP) identified in the context of neuroprotection.

Subsequent work showed the discovery wasn’t an isolated finding. Circulating humanin levels in centenarians (age 100+) are significantly higher than in age-matched controls in their 70s, with an inverse correlation between humanin concentration and all-cause mortality risk (Muzumdar et al., 2010, Cell Metabolism). That epidemiological association — a mitochondrial-derived peptide tracking with human longevity — pushed humanin into serious ageing research territory alongside MOTS-c and other MDPs.

How the humanin peptide works

Humanin’s mechanism runs through several parallel pathways. It’s a BAX inhibitor — it binds BAX directly and prevents BAX-mediated mitochondrial outer membrane permeabilisation, blocking the intrinsic apoptosis pathway in neurons and cardiomyocytes. It also activates STAT3 signalling, which has downstream effects on cell survival, metabolism, and inflammatory gene expression. And it binds formyl peptide receptor-like-1 (FPRL1/FPR2), a G-protein-coupled receptor expressed on immune cells and neurons, which mediates some of its anti-inflammatory and metabolic effects independently of BAX inhibition.

In practice, these pathways converge on a cytoprotective phenotype: cells that are under metabolic or amyloid stress survive better when humanin is present. The magnitude of effect in rodent models is dose-dependent and tissue-specific — neuronal and cardiac protection are the best-studied applications, but insulin-sensitive tissues also show response through the FPR2/metabolic pathway.

Humanin and insulin sensitivity

The metabolic data came later than the neurological data but is equally compelling. Humanin activates the FPR2 receptor on insulin-sensitive cells and appears to enhance insulin signalling downstream. In aged rodent models, exogenous humanin administration improves glucose tolerance and reduces insulin resistance — effects mediated partly through the BAX/apoptosis pathway in pancreatic beta cells (protecting them from lipotoxicity-induced death) and partly through direct FPR2-mediated signalling in skeletal muscle and liver.

The relevance: circulating humanin levels are significantly lower in patients with type 2 diabetes and metabolic syndrome compared to age-matched controls without these conditions. Whether that’s cause or consequence is still being worked out. But the mechanistic story is coherent — humanin protects both the neurons and the beta cells that maintain glucose homeostasis, which would explain why its decline correlates with both cognitive and metabolic deterioration with ageing.

What diseases is humanin linked to in research?

Alzheimer’s disease is where most of the mechanistic work sits. The original discovery paper showed BAX-mediated apoptosis protection in neurons challenged with amyloid-beta, and subsequent work in APP/PS1 transgenic mice (the standard AD model) demonstrated that humanin administration reduces plaque burden and improves spatial memory performance. The effect isn’t curative — it doesn’t clear existing pathology — but it appears to slow accumulation and protect surviving neurons.

Beyond neurodegeneration, the disease list includes cardiovascular disease (humanin levels are lower in patients with atherosclerosis and correlate inversely with cardiovascular event risk), metabolic syndrome, and age-related sarcopenia. The common thread is mitochondrial dysfunction: in all these conditions, mitochondria are failing in cell types where humanin is normally expressed or needed. Whether humanin deficiency is causal or simply a marker of mitochondrial failure is an open research question that the current literature hasn’t resolved.

Humanin-like peptides and analogues

Several humanin analogue molecules have been developed to improve pharmacokinetics or potency. The most-studied is HNG (S14G-humanin), which has an alanine-to-glycine substitution at position 14 that increases potency roughly 1000-fold. Other variants include Colivelin (a humanin-AGA(C8R)-HNG17 chimera) and the family of small humanin-like peptides (SHLP1 through SHLP6) encoded by adjacent mitochondrial reading frames. Each variant addresses different research questions depending on the target tissue and stability profile.

Comparison with other mitochondrial-derived peptides

Humanin sits within a small family of mitochondrial-derived peptides that includes MOTS-c (12 amino acids, from the 12S rRNA), SHLP1-6 (small humanin-like peptides from adjacent reading frames in 16S rRNA), and a handful of less-characterised ORF products. Each member of this family signals a slightly different stress condition: MOTS-c reports primarily on energetic stress and AMPK activation, the SHLPs cover apoptosis-related signalling adjacent to humanin, and humanin itself is the most-studied cytoprotective signal. Researchers comparing the family members should account for the differences in target tissue (humanin and SHLP3 favour neurons; MOTS-c favours skeletal muscle and adipose) and the differences in receptor pharmacology.

Safety and side effects

Reported safety signals from rodent studies are minimal at standard preclinical doses. The peptide is endogenous and well-tolerated in chronic-dosing protocols. Documented side effects in animal models are limited to mild injection-site reactions. The off-target risk profile of exogenous humanin or humanin-like peptide administration is not fully characterised in long-term human studies; the human exposure dataset is small because no humanin-based pharmaceutical has reached late-phase trials.

Dosing and routes of administration

Published research uses humanin and HNG by intraperitoneal, subcutaneous, and intracerebroventricular routes depending on the target tissue. Standard rodent doses range from 0.1 to 10 mg/kg/day for systemic studies; intracerebroventricular continuous infusion uses much lower amounts (nanogram quantities). The peptide is supplied as a lyophilised powder for reconstitution in bacteriostatic water and has limited room-temperature stability.

Regulatory and legal status

Humanin isn’t approved by Health Canada or the FDA for any therapeutic indication. It is legal in Canada and the United States as a research chemical sold under research-use-only labelling. No humanin-based pharmaceutical has reached late-phase clinical trials at the time of writing. The peptide is not on the World Anti-Doping Agency prohibited list.

Sourcing for research

Reproducible mitochondrial-derived peptide research depends on the integrity of the input material. Four supplier checks matter:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace
• Mass spectrometry verification of the expected ~2,687 Da molecular weight for humanin (different for HNG and SHLPs)
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies humanin with third-party COA and HPLC purity confirmation. View the Reviv Peptides shop for current availability.

Humanin peptide questions

What are the benefits of humanin peptide?

Documented benefits in rodent and cell-culture research include neuroprotection against Alzheimer’s-type damage, insulin sensitisation in type 2 diabetes models, cardioprotection in ischemia-reperfusion injury, and reduced atherosclerotic plaque burden. The mechanism centres on BAX inhibition and STAT3-mediated survival signalling.

What diseases is humanin linked to?

Alzheimer’s disease, type 2 diabetes, atherosclerosis, ischemia-reperfusion injury, and general aging biology. Low circulating humanin levels correlate with disease severity in several of these contexts.

What is the best peptide for anti-aging?

Endpoint-dependent. Humanin is among the strongest tools for mitochondrial stress and apoptosis components of aging. Other mitochondrial-derived peptides (MOTS-c), telomere-axis peptides (epitalon), and SS-31 cover different aging hallmarks.

How does humanin peptide work?

Through three mechanisms: BAX inhibition at the mitochondrial outer membrane (preventing apoptosis), activation of FPRL1/2-CNTFR cell-surface receptors driving STAT3 anti-apoptotic signalling, and modulation of insulin/IGF signalling for metabolic effects.

What are humanin-like proteins?

Small humanin-like peptides SHLP1 through SHLP6 are encoded by adjacent mitochondrial reading frames and share overlapping bioactivity. HNG (S14G-humanin) is a synthetic humanin analogue with roughly 1000-fold higher potency than native humanin.

Key data point: Muzumdar et al. (2010, Cell Metabolism) showed circulating Humanin levels in centenarians (age 100+) were significantly higher than in age-matched controls in their 70s, with an inverse correlation between Humanin concentration and all-cause mortality risk — one of the first epidemiological associations between a mitochondrial-derived peptide and longevity in humans.

Summary

Humanin is a paradigm-shifting mitochondrial-derived peptide that signals cellular stress and engages cytoprotective mechanisms across neuronal, metabolic, and cardiovascular tissues. The peptide is encoded by the mitochondrial 16S rRNA gene, inhibits BAX-mediated apoptosis, activates STAT3-driven survival signalling, and improves insulin sensitivity in rodent models. It is linked to Alzheimer’s disease, type 2 diabetes, and atherosclerosis in published research, and circulating levels decline substantially with age. No therapeutic approval exists yet, but the molecular biology is one of the cleanest examples of mitochondrial-nuclear cross-talk in current peptide research. For aging-biology investigators, humanin is Among the most useful tool molecules in the mitochondrial-derived peptide family.

All products sold by Reviv Peptides are for research and educational purposes only and aren’t intended for human consumption. Not for diagnostic, therapeutic, or clinical use of any kind.